218 related articles for article (PubMed ID: 29026296)
1. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
[TBL] [Abstract][Full Text] [Related]
2. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
[TBL] [Abstract][Full Text] [Related]
3. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
Chan MC; Tan EC; Yang MC
Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
[TBL] [Abstract][Full Text] [Related]
5. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
6. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
Bloom CI; Elkin SL; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
9. Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β
Wittbrodt ET; Millette LA; Evans KA; Bonafede M; Tkacz J; Ferguson GT
Int J Chron Obstruct Pulmon Dis; 2019; 14():101-114. PubMed ID: 30613140
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
Bengtson LGS; DePietro M; McPheeters J; Fox KM
Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
Strange C; Walker V; DePietro M; Tong J; Kurlander J; Carlyle M; Millette LA; Wittbrodt E
Int J Chron Obstruct Pulmon Dis; 2019; 14():1377-1388. PubMed ID: 31303751
[No Abstract] [Full Text] [Related]
12. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
[TBL] [Abstract][Full Text] [Related]
13. Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study.
Kozma CM; Paris AL; Plauschinat CA; Slaton T; Mackowiak JI
BMC Pulm Med; 2011 Dec; 11():61. PubMed ID: 22192866
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
[TBL] [Abstract][Full Text] [Related]
15. Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings.
Park HJ; Lee JU; Jeon S; Lee HS; Kim BY; Chae YJ; Kim GO; Park JW; Lee JH
PLoS One; 2024; 19(6):e0304362. PubMed ID: 38857214
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
Nagar S; Patel J; Stanford RH
Manag Care; 2018 May; 27(5):40-47. PubMed ID: 29763411
[TBL] [Abstract][Full Text] [Related]
17. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.
Bogart M; Stanford RH; Laliberté F; Germain G; Wu JW; Duh MS
Int J Chron Obstruct Pulmon Dis; 2019; 14():343-352. PubMed ID: 30863037
[TBL] [Abstract][Full Text] [Related]
18. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
Ivanov Y; Nikolaev I; Nemeth I
Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
[TBL] [Abstract][Full Text] [Related]
19. Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.
Bishwakarma R; Zhang W; Kuo YF; Sharma G
Int J Chron Obstruct Pulmon Dis; 2017; 12():477-486. PubMed ID: 28203071
[TBL] [Abstract][Full Text] [Related]
20. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.
Rogliani P; Calzetta L; Matera MG; di Daniele N; Girolami A; Cazzola M; Ora J
Expert Opin Pharmacother; 2019 Apr; 20(6):737-750. PubMed ID: 30707637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]